Sanofi is close to a $11.4 billion deal for Bioverativ: source
January 21, 2018 at 22:24 PM EST
The French drugmaker is nearing a deal to acquire biotechnology company Bioverativ for $105 a share.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.